226 related articles for article (PubMed ID: 37116111)
21. Neoadjuvant therapy for high-risk bulky regional melanoma.
Tarhini AA; Pahuja S; Kirkwood JM
J Surg Oncol; 2011 Sep; 104(4):386-90. PubMed ID: 21858833
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.
Rohaan MW; Stahlie EHA; Franke V; Zijlker LP; Wilgenhof S; van der Noort V; van Akkooi ACJ; Haanen JBAG
BMC Cancer; 2022 Aug; 22(1):851. PubMed ID: 35927710
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant immunotherapy for melanoma.
Lee AY; Brady MS
J Surg Oncol; 2021 Mar; 123(3):782-788. PubMed ID: 33002195
[TBL] [Abstract][Full Text] [Related]
24. Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma.
Miura JT; Zager JS
Future Oncol; 2019 Nov; 15(32):3665-3674. PubMed ID: 31538818
[TBL] [Abstract][Full Text] [Related]
25. Optimal systemic therapy for high-risk resectable melanoma.
Eggermont AMM; Hamid O; Long GV; Luke JJ
Nat Rev Clin Oncol; 2022 Jul; 19(7):431-439. PubMed ID: 35468949
[TBL] [Abstract][Full Text] [Related]
26. A safety review of recently approved and late-stage trial treatments for metastatic melanoma: systemic and regional therapies.
Perez MC; Depalo DK; Zager JS
Expert Opin Drug Saf; 2023; 22(9):789-797. PubMed ID: 37551723
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant Therapy for Melanoma.
Lowe MC; Kudchadkar RR
Surg Oncol Clin N Am; 2020 Jul; 29(3):445-453. PubMed ID: 32482319
[TBL] [Abstract][Full Text] [Related]
28. Management of In-Transit Metastases.
Queiroz MM; Bertolli E; Belfort FA; Munhoz RR
Curr Oncol Rep; 2022 May; 24(5):573-583. PubMed ID: 35192119
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing.
van Akkooi ACJ; Zijlker LP; Wouters MWJM
BioDrugs; 2022 May; 36(3):373-380. PubMed ID: 35397089
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous Melanoma - A Review of Systemic Therapies.
Lee KA; Nathan P
Acta Derm Venereol; 2020 Jun; 100(11):adv00141. PubMed ID: 32346745
[TBL] [Abstract][Full Text] [Related]
31. Which adjuvant treatment for patients with BRAF
Funck-Brentano E; Malissen N; Roger A; Lebbé C; Deilhes F; Frénard C; Dréno B; Meyer N; Grob JJ; Tétu P; Saiag P
Ann Dermatol Venereol; 2021 Sep; 148(3):145-155. PubMed ID: 33579557
[TBL] [Abstract][Full Text] [Related]
32. Preoperative therapy in melanoma: Evolving perspectives in clinical trials.
Kakish H; Xu K; Ahmed FA; Loftus AW; Elshami M; Hoehn RS; Ammori JB; Mangla A; Rothermel LD
Crit Rev Oncol Hematol; 2024 Jan; 193():104193. PubMed ID: 37926375
[TBL] [Abstract][Full Text] [Related]
33. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.
Tetzlaff MT; Messina JL; Stein JE; Xu X; Amaria RN; Blank CU; van de Wiel BA; Ferguson PM; Rawson RV; Ross MI; Spillane AJ; Gershenwald JE; Saw RPM; van Akkooi ACJ; van Houdt WJ; Mitchell TC; Menzies AM; Long GV; Wargo JA; Davies MA; Prieto VG; Taube JM; Scolyer RA
Ann Oncol; 2018 Aug; 29(8):1861-1868. PubMed ID: 29945191
[TBL] [Abstract][Full Text] [Related]
34. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.
Bhave P; Hong A; Lo SN; Johnson R; Mangana J; Johnson DB; Dulgar O; Eroglu Z; Yeoh HL; Haydon A; Lodde GC; Livingstone E; Khattak A; Kähler K; Hausschild A; McArthur GA; Menzies AM; Long G; Wang W; Carlino MS
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36889810
[TBL] [Abstract][Full Text] [Related]
36. The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges.
Stege H; Haist M; Nikfarjam U; Schultheis M; Heinz J; Pemler S; Loquai C; Grabbe S
Target Oncol; 2021 Sep; 16(5):537-552. PubMed ID: 34554353
[TBL] [Abstract][Full Text] [Related]
37. Predictive factors of neoadjuvant immune checkpoint blockade in melanoma.
Sarver M; Brown MC; Rhodin KE; Salama AKS; Beasley GM
Hum Vaccin Immunother; 2022 May; 18(3):1943987. PubMed ID: 34254900
[TBL] [Abstract][Full Text] [Related]
38. Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.
Rawson RV; Adhikari C; Bierman C; Lo SN; Shklovskaya E; Rozeman EA; Menzies AM; van Akkooi ACJ; Shannon KF; Gonzalez M; Guminski AD; Tetzlaff MT; Stretch JR; Eriksson H; van Thienen JV; Wouters MW; Haanen JBAG; Klop WMC; Zuur CL; van Houdt WJ; Nieweg OE; Ch'ng S; Rizos H; Saw RPM; Spillane AJ; Wilmott JS; Blank CU; Long GV; van de Wiel BA; Scolyer RA
Ann Oncol; 2021 Jun; 32(6):766-777. PubMed ID: 33744385
[TBL] [Abstract][Full Text] [Related]
39. Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma.
Reijers ILM; Rawson RV; Colebatch AJ; Rozeman EA; Menzies AM; van Akkooi ACJ; Shannon KF; Wouters MW; Saw RPM; van Houdt WJ; Zuur CL; Nieweg OE; Ch'ng S; Klop WMC; Spillane AJ; Long GV; Scolyer RA; van de Wiel BA; Blank CU
JAMA Surg; 2022 Apr; 157(4):335-342. PubMed ID: 35138335
[TBL] [Abstract][Full Text] [Related]
40. Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma.
Lucas MW; Versluis JM; Rozeman EA; Blank CU
Nat Rev Clin Oncol; 2023 Jun; 20(6):408-422. PubMed ID: 37147419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]